611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Medical Disorders
Basic InformationLookupsLatest News
Live Near a 'Superfund' Site? Your Life Span Might Be ShorterHormone Treatments May Raise Blood Pressure in Transgender PeopleUnexplained Drop in Resting Heart Rate in Youth 'Not a Good Thing'Common MS Meds Might Be Less Effective in Black PatientsIs It Allergies or COVID? Expert Shows How to Tell the DifferenceMany Employees Have Mixed Feelings as Offices ReopenHalf of American Adults Have Now Gotten at Least One COVID Vaccine ShotWarmer Climate, More Pollen, Worse Allergies: How to Fight BackCycling During Dialysis? It Might Help PatientsPregnancy Raises the Risk for Kidney StonesU.S. Marines Study Finds Getting COVID Won't Protect Young People From ReinfectionKnow the Signs of Rare Blood Clot Linked With J & J Vaccine1 in 50 COVID Patients in ICU Will Develop a StrokeBooster Shots a Likely Reality for COVID-Vaccinated AmericansAHA News: The Link Between Structural Racism, High Blood Pressure and Black People's HealthMost Young Americans Eager to Get COVID Vaccine: PollRashes Can Occur After COVID Vaccine,  But Dermatologists Say 'Don't Worry'Even Before COVID, Many More People Died Early in U.S. Versus EuropeCOVID Plus 'Bleeding' Stroke Doubles a Patient's Death RiskLower Rates of COVID in States That Mandated Masks: StudyCDC Panel Says It Needs More Time to Study J&J Vaccine Clotting CasesOne Good Way to Help Beat COVID: ExerciseDiabetes Can Lead to Amputations, But Stem Cell Treatment Offers HopeResearch Shows Links Between Gum Disease and Alzheimer'sNo Rise in Global Suicide Rate in First Months of PandemicCloth Masks Do Make Workouts a Bit Tougher, Study FindsMany Kids Who Develop Severe COVID-Linked Syndrome Have Neurologic SymptomsBiden, Fauci Say Pause in J&J COVID Vaccine Is Sign That Safety Comes FirstAHA News: Straight Answers to Common Questions About COVID-19 VaccinesJ&J Vaccine 'Pause' Is Not Mandate Against the Shot, FDA SaysU.K. Variant Won't Trigger More Severe COVID, Studies FindNewborns Won't Get COVID Through Infected Mom's Breast Milk: StudyU.S. Health Agencies Call for Pause in J&J COVID Vaccine After 6 People Develop ClotsUrinary Incontinence Surgery Won't Raise a Woman's Cancer RiskCOVID Vaccines Trigger Protective Immune Response in Nursing Home Residents: StudyCOVID Vaccines Might Not Protect Certain Cancer PatientsHad Facial Fillers? What You Need to Know About COVID VaccinesAntibody Cocktail May Curb Infection in Unvaccinated Who Are Exposed to COVID-19Scientists Find Clues to Why AstraZeneca's Vaccine May Cause ClotsYou've Got Fungi in Your Lungs, and That's OKNon-Emergency Surgeries Are Rebounding, But Backlogs RemainPandemic Has Put Many Clinical Trials on HoldSupply of J&J COVID Vaccine to Drop 86 Percent Next WeekStressed, Exhausted: Frontline Workers Faced Big Mental Strain in PandemicNIH Starts Trial Looking at Rare Allergic Reactions to COVID VaccinesNot Just Keyboards: Many Types of Workers Can Develop Carpal TunnelBlack Women Are Dying of COVID at Much Higher Rates Than White MenTwo Vaccines Show Effectiveness Against Emerging COVID VariantsWomen More Prone to Concussion's Long-Term Harms: StudyCOVID Cases Climb in the Midwest as British Variant Takes Hold in U.S.
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

New Variants Mean COVID Vaccines, Tests May Need Tweaking: FDA

HealthDay News
by By Dennis Thompson HealthDay Reporter
Updated: Feb 22nd 2021

new article illustration

MONDAY, Feb. 22, 2021 (HealthDay News) -- The emergence of new SARS-CoV-2 variants could require a quick pivot on the part of pharmaceutical and medical device companies, to help stay one step ahead of COVID-19.

The U.S. Food and Drug Administration issued guidelines Monday encouraging drug and test developers to pay attention to new coronavirus variants and be prepared to make that pivot if necessary.

The guidance provides recommendations for companies seeking to tweak already-approved vaccines, medicines and tests so that they will remain effective against any new variants that emerge.

"Many of these products might be impacted by changes to the virus, particularly their efficacy or their performance," acting FDA Commissioner Dr. Janet Woodcock said during a media briefing Monday.

"We recognize we are in a pandemic situation and we need to make sure that health care providers have the best available diagnostics, therapeutics and vaccines to fight the virus. These may need to be modified over time to remain maximally effective," Woodcock added.

The emergence of highly infectious new SARS-CoV-2 variants out of the United Kingdom, South Africa and Brazil have raised concerns that mutations might weaken the effectiveness of vaccines and drugs now used to treat the disease.

Studies have shown that the two vaccines now on the market remain effective in thwarting the U.K. and South African variants of the virus that causes COVID-19, but experts are worried that monoclonal antibody treatments might not work as well.

"Monoclonal antibodies are laboratory-made proteins that mimic the immune system in fighting off harmful pathogens such as viruses," Woodcock said. "We know that some of the monoclonal antibodies that are currently authorized are less active against some of the SARS-CoV-2 variants that have emerged and are prevalent in some parts of the world."

There are similar concerns about the effectiveness of COVID-19 tests to detect the new variants. The FDA has already issued a safety alert to caution that the presence of viral genetic mutations in a patient sample can potentially change the performance of a diagnostic test.

"The FDA has identified a few tests that are known to be impacted by emerging viral mutations, although at this time the impact does not appear to be significant," Woodcock said.

The agency also issued guidance to help pharmaceutical companies prepare for tweaks to vaccines if a new variant emerges that flouts the antibody protection provided by the Pfizer and Moderna vaccines.

Companies should be prepared to test either reworked vaccines or new booster shots that would protect against emerging variants, after smaller-scale clinical trials that would involve a few hundred people and last two or three months, Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said during Monday's briefing.

"We think it's prudent to start doing clinical trials," Marks said, later adding, "We are encouraging people to start them sooner rather than later, without necessarily triggering production yet."

More information

The U.S. Centers for Disease Control and Prevention has more on coronavirus variants.

SOURCES: Feb. 22, 2021, media briefing with: U.S. Food and Drug Administration Commissioner Janet Woodcock, MD; Peter Marks, MD, PhD, director, FDA's Center for Biologics Evaluation and Research